xmlns:atom="http://www.w3.org/2005/Atom" xmlns:atom="http://www.w3.org/2005/Atom"
Regulation 5
1. The following medicinal products shall be available only on prescription—U.K.
(a)a product for parenteral administration;
(b)a product that is a controlled drug [F1as defined in section 2(1)(a) of the Misuse of Drugs Act 1971], unless it is covered by a marketing authorisation in which the product is classified as a pharmacy medicine or as a medicinal product subject to general sale;
(c)cyanogenic substances, other than preparations for external use;
(d)medicinal substances that on administration emit radiation, or contain or generate any substance which emits radiation, in order that radiation may be used;
(e)a product that—
(i)is covered by a marketing authorisation in which the product is classified as a pharmacy medicine or as a medicinal product subject to general sale, and
(ii)consists of or contains aloxiprin, aspirin or paracetamol in the form of non-effervescent tablets or capsules;
(f)a product that—
(i)is covered by a marketing authorisation in which the product is classified as a pharmacy medicine or as a medicinal product subject to general sale, and
(ii)consists of or contains (in any pharmaceutical form) pseudoephedrine salts or ephedrine base or salts; and
(g)a product that—
(i)is not covered by a marketing authorisation, and
(ii)is a prescription only medicine by virtue of articles 5 and 10 of, and Schedules 1 and 2 to, the Prescription Only Medicines (Human Use) Order 1997 M1.
Textual Amendments
F1Words in Sch. 1 para. 1(b) inserted (E.W.S.) (31.3.2014) by The Human Medicines (Amendment) Regulations 2014 (S.I. 2014/490), regs. 1(2), 10 and words in Sch. 1 para. 1(b) inserted (N.I.) (31.3.2014) by The Human Medicines (Amendment) Regulations 2014 (S.R. 2014/323), regs. 1(2), 10
Marginal Citations
M1S.I. 1997/1830, as amended by S.I. 1997/2044, S.I. 1998/108, S.I. 1998/1178, S.I. 1998/2081, S.I. 1999/1044, S.I. 1999/3463, S.I. 2000/1917, S.I. 2000/2899, S.I. 2000/3231, S.I. 2001/2777, S.I. 2001/3942, S.I. 2003/696 and S.I. 2006/915 and these Regulations. There are other amendments, but none is relevant.
2. In this Part “cyanogenic substances” means preparations which—U.K.
(a)are presented for sale or supply under the name of, or as containing, amygdalin, laetrile or vitamin B17; or
(b)contain more than 0.1 per cent by weight of any substance having the formula either—
(i)alpha-Cyanobenzyl -6-O-Beta-d-glucopyranosyl -Beta-d-glucopyranoside, or
(ii)alpha-Cyanobenzyl -Beta-d-glucopyranosiduronic acid.
3. The following medicinal products shall be available only from a pharmacy—U.K.
(a)a product comprising eye ointment;
(b)a product that contains Vitamin A, Vitamin A acetate or Vitamin A palmitate, in each case with a maximum daily dose equivalent to more than 7500 international units of Vitamin A or 2250 micrograms of retinol;
(c)a product that contains Vitamin D with a maximum daily dose of more than 400 units of antirachitic activity.
4. The following medicinal products shall be available only from a pharmacy unless they are the subject of a marketing authorisation or traditional herbal registration that classifies them as medicinal products subject to general sale—U.K.
(a)a product that is for use as an anthelmintic;
(b)a product that is for parenteral administration;
(c)a product that is for use as an enema;
(d)a product that is for use wholly or mainly for irrigation of—
(i)wounds, or
(ii)the bladder, vagina or rectum;
(e)a product that is for administration wholly or mainly to children being a preparation of aloxiprin or aspirin.
5. A medicinal product shall be available only from a pharmacy if it is a medicinal product of a kind specified in Schedule 15 but is not presented for sale in accordance with the requirements specified in that Schedule for a product of that kind to be subject to general sale.U.K.